Consequently, the theoretical decoupling of cytotoxic effects and ACE2 upregulation through the administration of agents inhibiting ACE2 emerges as a promising therapeutic strategy in the nuanced management of aggressive breast cancer. The gene discussed is ACE2; the disease is breast cancer.